文献速递糖尿病

自动化胰岛素输注在7岁以下1型糖尿病患儿中的系统评价与荟萃分析

Automated insulin delivery in young children with type 1 diabetes: a systematic review and meta-analysis.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

结果显示AID使目标范围内时间(TIR)平均提高9.88%(95%CI 9.14至10.62),约合每天2.37小时,日间与夜间均改善,低血糖暴露无显著变化,严重低血糖与糖尿病酮症酸中毒少见。

要点

  • AID使7岁以下患儿TIR平均提高9.88%,约合每天2.37小时。
  • 夜间TIR改善幅度(16.85%)明显大于日间(6.88%)。
  • 各AID设备TIR改善相近,低血糖暴露无显著变化,安全性良好。

核心结论

  • AID系统可改善7岁以下1型糖尿病患儿的血糖结局,且安全性良好。

研究设计与样本

  • 纳入30项研究(9项随机对照试验、7项单臂研究、14项队列研究),共1155名7岁以下患儿。
  • 采用随机效应模型计算合并估计值,以均数变化(MC)及95%CI表示。

主要发现

  • TIR平均提高9.88%(95%CI 9.14至10.62),I2=8%,P<.0001,证据确定性中等,相当于每天2.37小时。
  • 日间TIR提高6.88%(95%CI 5.70至8.07),夜间提高16.85%(95%CI 13.48至20.22)。
  • 各设备TIR改善:MiniMed 670G为9.65%,MiniMed 780G为10.04%,CamAPS FX为10.58%,Control-IQ为9.51%,Omnipod 5为10.25%,Open Source为6.77%。
  • AID使用与高血糖暴露减少及糖化血红蛋白适度下降相关,低血糖暴露无显著变化。
  • 严重低血糖和糖尿病酮症酸中毒事件少见。

临床怎么用

  • 对7岁以下1型糖尿病患儿,可考虑使用AID系统以提升TIR并减少高血糖暴露。
  • 夜间血糖改善尤为明显,提示AID对夜间血糖管理有额外价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Automated insulin delivery (AID) in young children (<7 years) with type 1 diabetes has not yet been systematically evaluated. MATERIALS AND METHODS: Web of Science, PubMed, Scopus, CENTRAL, and ClinicalTrials.gov were searched from inception to December 9, 2025. Studies reporting glycemic outcomes in children younger than 7 years were included in this meta-analysis. Studies not published in English were excluded. The primary outcome was the change in time-in-range (TIR; 70-180 mg/dL). Pooled estimates were calculated using random-effects models and expressed as mean changes (MCs) with 95% confidence intervals (CIs). RESULTS: This study included 30 studies (9 randomized controlled trials, 7 single-arm studies, and 14 cohort studies) involving 1155 young children. AID systems were associated with a significant increase in TIR (MC, 9.88% [95% CI 9.14 to 10.62], I2 = 8%, P < .0001, moderate certainty), equivalent to 2.37 hours/day. Favorable improvement was also observed during the daytime (MC, 6.88% [95% CI 5.70 to 8.07]) and overnight (MC, 16.85% [95% CI 13.48 to 20.22]). TIR improvements were comparable across devices: MiniMed 670G (9.65%), MiniMed 780G (10.04%), CamAPS FX (10.58%), Control-IQ (9.51%), Omnipod 5 (10.25%), and Open Source (6.77%). AID use was also associated with reduced hyperglycemia exposure and modest reductions in glycated hemoglobin, without significant changes in hypoglycemia exposure. Episodes of severe hypoglycemia and diabetic ketoacidosis were infrequent. CONCLUSION: This systematic review with meta-analysis revealed that AID systems have greater benefits for improving glycemic outcomes and have good safety profiles in young children with type 1 diabetes.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Oktavian P, Wungu CDK, Amin IM, et al. Automated insulin delivery in young children with type 1 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2026. PMID: 41877382. doi:10.1210/clinem/dgag133

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。